Multiplicom | GenomeWeb

Multiplicom

Agilent plans to pay approximately €68 million in cash, and the deal is expected to be completed by mid-January.

The company currently offers target amplification assays for diagnostic use and clinical research that are based on a proprietary multiplex PCR technology.

The firms plan to combine Sophia's DDM software with Multiplicom's molecular diagnostic kits, and sell the solution to European hospitals and laboratories.

The Belgian company is also developing new tests and applications with its Multiplex Amplification of Specific Targets for Resequencing technology.

The BRCA Tumor MASTR Plus Dx assay identifies somatic mutations in the BRCA1 and BRCA2 genes in FFPE tumor tissue from ovarian cancer patients.

The non-invasive test is designed to detect chromosomal abnormalities in the fetus to reduce the number of pregnant women undergoing invasive procedures. 

The companies are taking the CE-IVD route as opposed to the LDT model in the US due to Europe's distributed prenatal testing market and lower regulatory hurdles.

NEW YORK (GenomeWeb) – Researchers affiliated with the University of Antwerp and Antwerp University Hospital have partnered with molecular diagnostics firm Multiplicom to develop a test to help identify individuals at risk for sudden cardiac death.

Belgian company Multiplicom has launched a CE-IVD labeled MID kit for Illumina's MiSeq system as well as three germline mutation detection kits using the company's MASTR technology for maturity onset diabetes of the young, autoso

GATC Biotech subsidiary LifeCodexx has launched a new version of its noninvasive fetal aneuploidy test, PraenaTest Express, that has a turnaround time of one week.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.